Literature DB >> 21092073

Pressure-independent cerebrovascular remodelling and changes in myogenic reactivity in diabetic Goto-Kakizaki rat in response to glycaemic control.

A Kelly-Cobbs1, M M Elgebaly, W Li, A Ergul.   

Abstract

AIM: We have shown hypertrophic cerebrovascular remodelling in the Goto-Kakizaki (GK) rat model of diabetes. This study tested the hypotheses that (1) vascular remodelling develops as the disease progresses and alters myogenic reactivity of resistance vessels important for regulation of cerebral blood flow (CBF), and (2) glycaemic control prevents cerebrovascular remodelling and myogenic dysfunction.
METHODS: Middle cerebral artery (MCA) lumen diameter, media : lumen (M : L) ratio, cross-sectional area (CSA) and myogenic tone were measured in 10- and 18-week-old control Wistar and diabetic GK rats using pressurized arteriograph (n = 8-14/group). Mean arterial blood pressure (MAP) was measured with telemetry (n = 5/group). Additional GK rats were treated with metformin (300 mg kg(-1) day(-1) ) for glycaemic control starting at 7 weeks after the onset of diabetes until 18 weeks (n = 9).
RESULTS: In the control group, there was no difference in remodelling indices, myogenic tone or MAP between ages. Eighteen week diabetic rats displayed increased M : L ratio and CSA, but decreased lumen diameter and myogenic tone compared to 10-week GK or 18-week control rats. MAP increased starting around 10 weeks of age and remained slightly higher in the GK rats. Glycaemic control normalized M : L ratio, CSA, lumen diameter and myogenic tone with no effect on blood pressure.
CONCLUSIONS: These findings suggest that diabetic rats develop MCA remodelling as the disease progresses but this is associated with impaired myogenic reactivity which may ultimately affect CBF. Our results also provide evidence that glycaemic control is an effective therapeutic strategy to prevent cerebrovascular remodelling and dysfunction.
© 2011 The Authors. Acta Physiologica © 2011 Scandinavian Physiological Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21092073      PMCID: PMC3734544          DOI: 10.1111/j.1748-1716.2010.02230.x

Source DB:  PubMed          Journal:  Acta Physiol (Oxf)        ISSN: 1748-1708            Impact factor:   6.311


  23 in total

1.  Spironolactone improves structure and increases tone in the cerebral vasculature of male spontaneously hypertensive stroke-prone rats.

Authors:  Christine' S Rigsby; David M Pollock; Anne M Dorrance
Journal:  Microvasc Res       Date:  2007-01-23       Impact factor: 3.514

2.  Effects of ischemia and myogenic activity on active and passive mechanical properties of rat cerebral arteries.

Authors:  Rebecca J Coulson; Naomi C Chesler; Lisa Vitullo; Marilyn J Cipolla
Journal:  Am J Physiol Heart Circ Physiol       Date:  2002-08-29       Impact factor: 4.733

3.  Glycemic control prevents microvascular remodeling and increased tone in type 2 diabetes: link to endothelin-1.

Authors:  Kamakshi Sachidanandam; Jim R Hutchinson; Mostafa M Elgebaly; Erin M Mezzetti; Anne M Dorrance; Kouros Motamed; Adviye Ergul
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2009-01-28       Impact factor: 3.619

4.  Glucose Regulation in Acute Stroke Patients (GRASP) trial: a randomized pilot trial.

Authors:  Karen C Johnston; Christiana E Hall; Brett M Kissela; Thomas P Bleck; Mark R Conaway
Journal:  Stroke       Date:  2009-10-15       Impact factor: 7.914

5.  Intensive glucose therapy and clinical implications of recent data: a consensus statement from the Global Task Force on Glycaemic Control.

Authors:  S Akalin; K Berntorp; A Ceriello; A K Das; E S Kilpatrick; T Koblik; C S Munichoodappa; C Y Pan; W Rosenthall; M Shestakova; B Wolnik; V Woo; W Y Yang; M T Yilmaz
Journal:  Int J Clin Pract       Date:  2009-10       Impact factor: 2.503

6.  Treatment of hyperglycemia in ischemic stroke (THIS): a randomized pilot trial.

Authors:  Askiel Bruno; Thomas A Kent; Bruce M Coull; Ravi R Shankar; Chandan Saha; Kyra J Becker; Brett M Kissela; Linda S Williams
Journal:  Stroke       Date:  2007-12-20       Impact factor: 7.914

7.  Myogenic tone and reactivity of cerebral arteries in type II diabetic BBZDR/Wor rat.

Authors:  Yagna P R Jarajapu; Dennis L Guberski; Maria B Grant; Harm J Knot
Journal:  Eur J Pharmacol       Date:  2007-10-25       Impact factor: 4.432

8.  Differential effects of ET(A) and ET(B) receptor antagonism on oxidative stress in type 2 diabetes.

Authors:  Mostafa M Elgebaly; Vera Portik-Dobos; Kamakshi Sachidanandam; David Rychly; Daniel Malcom; Maribeth H Johnson; Adviye Ergul
Journal:  Vascul Pharmacol       Date:  2007-06-06       Impact factor: 5.773

9.  Mechanical properties of rat middle cerebral arteries with and without myogenic tone.

Authors:  Rebecca J Coulson; Marilyn J Cipolla; Lisa Vitullo; Naomi C Chesler
Journal:  J Biomech Eng       Date:  2004-02       Impact factor: 2.097

10.  Intensive glycemic control and the prevention of cardiovascular events: implications of the ACCORD, ADVANCE, and VA diabetes trials: a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association.

Authors:  Jay S Skyler; Richard Bergenstal; Robert O Bonow; John Buse; Prakash Deedwania; Edwin A M Gale; Barbara V Howard; M Sue Kirkman; Mikhail Kosiborod; Peter Reaven; Robert S Sherwin
Journal:  Diabetes Care       Date:  2008-12-17       Impact factor: 17.152

View more
  20 in total

Review 1.  Cerebrovascular complications of diabetes: focus on stroke.

Authors:  Adviye Ergul; Aisha Kelly-Cobbs; Maha Abdalla; Susan C Fagan
Journal:  Endocr Metab Immune Disord Drug Targets       Date:  2012-06       Impact factor: 2.895

Review 2.  Renal autoregulation in health and disease.

Authors:  Mattias Carlström; Christopher S Wilcox; William J Arendshorst
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

3.  Linagliptin treatment improves cerebrovascular function and remodeling and restores reduced cerebral perfusion in Type 2 diabetes.

Authors:  Trevor Hardigan; Abdul Yasir; Mohammed Abdelsaid; Maha Coucha; Sally El-Shaffey; Weiguo Li; Maribeth H Johnson; Adviye Ergul
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2016-06-29       Impact factor: 3.619

Review 4.  Cerebrovascular complications of diabetes: focus on cognitive dysfunction.

Authors:  Trevor Hardigan; Rebecca Ward; Adviye Ergul
Journal:  Clin Sci (Lond)       Date:  2016-10-01       Impact factor: 6.124

5.  Type 2 diabetes mellitus in the Goto-Kakizaki rat impairs microvascular function and contributes to premature skeletal muscle fatigue.

Authors:  Jefferson C Frisbee; Matthew T Lewis; Jonathan D Kasper; Paul D Chantler; Robert W Wiseman
Journal:  J Appl Physiol (1985)       Date:  2018-12-20

Review 6.  Cerebral Vascular Disease and Neurovascular Injury in Ischemic Stroke.

Authors:  Xiaoming Hu; T Michael De Silva; Jun Chen; Frank M Faraci
Journal:  Circ Res       Date:  2017-02-03       Impact factor: 17.367

7.  Accelerated cerebral vascular injury in diabetes is associated with vascular smooth muscle cell dysfunction.

Authors:  Ya Guo; Shaoxun Wang; Yedan Liu; Letao Fan; George W Booz; Richard J Roman; Zongbo Chen; Fan Fan
Journal:  Geroscience       Date:  2020-03-12       Impact factor: 7.713

8.  Late dual endothelin receptor blockade with bosentan restores impaired cerebrovascular function in diabetes.

Authors:  Mohammed Abdelsaid; Handong Ma; Maha Coucha; Adviye Ergul
Journal:  Life Sci       Date:  2014-01-13       Impact factor: 5.037

9.  Protein nitration impairs the myogenic tone of rat middle cerebral arteries in both ischemic and nonischemic hemispheres after ischemic stroke.

Authors:  Maha Coucha; Weiguo Li; Maribeth H Johnson; Susan C Fagan; Adviye Ergul
Journal:  Am J Physiol Heart Circ Physiol       Date:  2013-10-04       Impact factor: 4.733

10.  Cerebrovasculoprotective effects of azilsartan medoxomil in diabetes.

Authors:  Mohammed Abdelsaid; Maha Coucha; Adviye Ergul
Journal:  Transl Res       Date:  2014-06-17       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.